La catena delle opzioni mostra i dati chiave delle opzioni azionarie di Synaptogenix a vari prezzi di esercizio e date di scadenza. I trader utilizzano queste informazioni per analizzare potenziali operazioni e valutare il sentiment del mercato per Synaptogenix..

Synaptogenix (NASDAQ:SNPX) Azioni, Catena delle Opzioni

Synaptogenix

Synaptogenix Inc is a biopharmaceutical company with product candidates in pre-clinical and clinical development. It is principally focused on developing a product platform based upon a drug candidate called bryostatin for the treatment of Alzheimer's disease, which is in the clinical testing stage. It is also evaluating bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as Fragile X syndrome, Multiple Sclerosis, and Niemann-Pick Type C disease, which have undergone pre-clinical testing.

Synaptogenix Inc

SNP SCHNEIDER NEUREITHER by SNP Schneider Neureither & Partner AG

SNP Schneider-Neureither & Partner SE

Good Morning Traders! In today&#39;s Market Clubhouse Morning Memo, we will discuss SPY, QQQ, AAPL, MSFT, NVDA, GOOGL, META, and TSLA.
Our proprietary formula, exclusive to Market Clubhouse, dictates these price levels. This dynamic equation takes into account price, volume, and options flow. These levels are updated every day and shared with all Clubhouse Members, prior to the opening of the market.
We recommend closely monitoring these stocks, and be prepared to leverage potential breakouts or reversals. As always, stay alert and ready to adjust your tactics based on the market&#39;s pulse to optimize your trading gains. Now, let&#39;s dive into the stock analysis:
<h3>SPDR S&amp;P 500 ETF Trust </h3>
SPY&nbsp;(ARCA: SPY) is currently holding near our focal level of 571.06. For bullish momentum, we&#39;d like to see an early advance to 572.15. If price action shows resilience above 572.15, we&rsquo;re expecting buyers to extend the price to the support area of 573.50. A steady hold above 573.60 during regular trading hours could set up a move to the next target at 574.65, with our high bull target for the session at 575.67.
On the downside, failure to sustain above 571.06 may invite bearish pressure. In that scenario, we&#39;re watching for a test at 569.98. Persistent selling could see bears challenge lower support at 569.16, and a deeper breakdown could drive SPY down to a firm support at 567.81. In a high-volatility session, our low bear target for SPY is positioned at 566.46.
<h3>Invesco QQQ Trust Series 1</h3>
The QQQ (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/qqq#NASDAQ">QQQ</a>) is currently navigating around our level of 487.69. For bullish action, buyers should defend this level and aim to push up towards 490.05. A confirmed hold above 490.05 could bring 491.82 into play, showing renewed buyer confidence. If momentum holds, we&rsquo;re looking for a potential move higher to 493.60, with our optimistic bull target set at 495.35 for the day.
If QQQ struggles to hold above 487.69 in today&rsquo;s session, it may present an opportunity for bears to step in. A move lower could challenge 486.10, and persistent weakness could see further downside to 483.95. If sellers remain active, a test of 481.73 is likely. Should selling intensify, the low bear target for QQQ today sits at 479.03.
<h3>Apple Inc.</h3>
Apple&nbsp;(NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/aapl#NASDAQ">AAPL</a>) is currently trading around our identified level of 221.66. Bulls will be looking for 222.24 to provide a base for a push higher. Should the auction hold above 222.24, the next upward target is 222.96, signaling bullish continuation. If buying momentum remains, we anticipate a test of 223.87, with the high bull target for Apple placed at 225.31.
If Apple fails to maintain support at 221.66, we could see a bearish test lower toward 220.97. Continued selling might drive the price down to 220.29, with bears pushing further if downward pressure persists. A breakdown here could lead Apple toward 219.19, and if this level fails, our low bear target for the day is at 218.08.
<h3>Microsoft Corp. </h3>
Microsoft&nbsp;(NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/msft#NASDAQ">MSFT</a>) is currently situated near our key level of 409.69. Bulls will look to defend this area and drive prices up toward 410.64. If this level solidifies as support, we may see a continuation rally toward 411.72. Consistent buyer strength today could lead Microsoft to its high bull target of 413.14.
A failure to hold 409.69 as support could open the door for a bearish test at 408.46. If bearish sentiment dominates, 407.11 may come into play as the next lower support. Continued selling pressure could lead Microsoft down to 406.01, with the day&rsquo;s low bear target set at 404.92 if sellers maintain control.
<h3>NVIDIA Corporation </h3>
NVIDIA&nbsp;(NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/nvda#NASDAQ">NVDA</a>) is auctioning near our level of 136.98. For a bullish session, we want to see the price advance to 137.94, holding this level as a base for upward movement. If buyers maintain this level, we may see a rally toward 138.55. Sustained buying could lift NVIDIA to our high bull target of 140.28.
If NVIDIA breaks below 136.98, bearish momentum could bring it down to test support at 135.64. Persistent selling might push the auction lower to 134.56. Should the downtrend continue, a test at 133.31 is expected, with the low bear target of 132.19 if the session weakens further.
<h3>Alphabet Inc Class A</h3>
Alphabet (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/googl#NASDAQ">GOOGL</a>) is currently near our level of 169.34. Bulls aim to uphold this level, pushing the price toward 171.14. If the auction stabilizes above 171.14, we may see a potential test of our high bull target at 172.28.
If 169.34 breaks down as support, bears may attempt to drive prices lower to 167.04. Sustained selling could press GOOGL down to 165.41, and if selling intensifies, the low bear target for the day is positioned at 163.79.
<h3>Meta Platforms Inc </h3>
Meta&nbsp;(NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/meta#NASDAQ">META</a>) is currently balancing around 565.53. Bulls will want to see this level held firmly, allowing the price to rise toward 573.25. If buyers maintain their strength, we could see an extension to 580.17, aiming for the high bull target at 585.73.
If Meta fails to keep support at 565.53, bearish movement could drive the price down to 559.29. Further selling pressure might bring 553.05 into play, and if the downside trend continues, the low bear target for Meta is set at 548.44.
<h3>Tesla Inc. </h3>
Tesla&nbsp;(NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/tsla#NASDAQ">TSLA</a>) is auctioning near our level of 248.37. Bulls will look to push higher to 250.25 and sustain the buying momentum above this level. If strong demand persists, we could see Tesla testing 252.38, with further upside bringing the high bull target at 256.34 into play.
If Tesla fails to hold 248.37 as a base, bears might seize control and drive prices toward 246.16. A break below this level could lead to a test at 243.98, with the low bear target set at 242.49 if selling pressure mounts.
Final Word: Today&#39;s trading session brings minimal economic data but some noteworthy events that could impact the markets. At 8:30 AM ET, the Trade Balance for September is set for release, offering insight into the country&rsquo;s export-import landscape. At 10 AM ET, the ISM Services Index for October will be published, providing a read on the strength of the service sector. Later, at 1 PM ET, the Treasury will conduct a 10-Year Note Auction, which could influence bond yields and overall market sentiment. Adding to the day&rsquo;s complexity, the U.S. Presidential Elections are taking place, and the outcomes could introduce unexpected volatility. This combination of factors calls for a cautious approach. Be prepared for quick market shifts, manage risk attentively, and trade safely amidst what may be a particularly unpredictable session. Best of luck in today&rsquo;s trade!
The Morning Memo is curated by RIPS, a pro trader with years of experience in equities, options, and futures trading. RIPS is at the heart of the exclusive Market Clubhouse community, offering his insights, expertise, and real-time mentorship.
Start your day with a live daily market analysis, a carefully selected watch list, early access to the Morning Memo, and exclusive Market Clubhouse price levels, providing precise support and resistance indicators. When you become a member of Market Clubhouse, you will gain early access to the Morning Memo, just like this one, every single day&mdash;hours before it&#39;s published. You will also have access to a live stream with zero latency and screen sharing, enabling you to witness Rips executing his trades in real-time and sharing his exclusive trading plans, strategies, and live decision-making.
For a limited time during our special promotion, you can join RIPS and get a full access pass to Market Clubhouse for 7 full days for just $7. Check it out at <a href="https://marketclubhouse.club/7Days/" title="https://marketclubhouse.club/7Days/">https://marketclubhouse.club/7Days/</a> where you can trade live with him and tap into his wealth of knowledge and experience. You can also catch Rips on his live day trading streams every Monday-Friday at 8 am EST on the Market Clubhouse YouTube channel: <a href="https://www.youtube.com/@MarketClubhouse" title="https://www.youtube.com/@MarketClubhouse">https://www.youtube.com/@MarketClubhouse</a>.
This article is from an unpaid external contributor. It does not represent Benzinga's reporting and has not been edited for content or accuracy.

Markets

Trading Ideas

General

AAPL

GOOGL

MSFT

NVDA

TSLA

Market Clubhouse Morning Memo - November 5th, 2024 (Trade Strategy For SPY, QQQ, AAPL, MSFT, NVDA, GOOGL, META And TSLA)

Wells Fargo analyst Elyse Greenspan maintains Allstate (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ALL#NYSE">ALL</a>) with a Equal-Weight and raises the price target from $175 to $186.

News

Price Target

Analyst Ratings

Wells Fargo Maintains Equal-Weight on Allstate, Raises Price Target to $186

WIIM

VRTX

Vertex Pharmaceuticals shares are trading higher after the company reported better-than-expected Q3 financial results and issued FY24 product revenue guidance above estimates. Also, Morgan Stanley maintained an Equal-Weight rating on the stock and raised its price target from $473 to $476.

Wells Fargo analyst Yanan Zhu maintains Editas Medicine (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EDIT#NASDAQ">EDIT</a>) with a Overweight and lowers the price target from $9 to $7.

EDIT

Wells Fargo Maintains Overweight on Editas Medicine, Lowers Price Target to $7

<a href="https://darkwebinformer.com/engineer-is-allegedly-selling-partner-portal-access-to-rapid7s-open-data/">https://darkwebinformer.com/engineer-is-allegedly-selling-partner-portal-access-to-rapid7s-open-data/</a>
&nbsp;
&#x1F517; DarkWebInformer.com - Cyber Threat Intelligence &#x1F4C5; Date: 2024-11-05 02:27:28 &#x1F6A8; Title: Alleged sale of partner portal access to Rapid7's Open Data &#x1F6E1;&#xFE0F; Victim Country: USA
&#x1F3ED; Victim Industry: Computer &amp; Network Security &#x1F3E2; Victim Organization: rapid7 &#x1F310; Victim Site: opendata.rapid7.com &#x1F4DC; Category: Data Breach &#x1F517; Claim: <a href="https://breachforums.st/Thread-PARTNER-PORTAL-ACCESS-TO-OPEN-DATA-RAPID7">https://breachforums.st/Thread-PARTNER-PORTAL-ACCESS-TO-OPEN-DATA-RAPID7</a> &#x1F575;&#xFE0F;&#x200D;&#x2642;&#xFE0F; Threat Actor: engineer &#x1F30D; Network: openweb &#x1F4DD; Description: The threat actor claims to be selling partner portal access to Rapid7's Open Data, which offers extensive data from Project Sonar's internet-wide surveys. Project Sonar collects global telemetry to identify common vulnerabilities, providing researchers with data to support public security projects. The alleged access includes 84.8 TB of data across 71,125 files, potentially enabling security insights for research, government security advocacy, and commercial security projects.

Rumors

Watching Rapid7; Traders Circulate Dark Web Informer Post Saying "Engineer Is Allegedly Selling Partner Portal Access To Rapid7's Open Data"

Wells Fargo analyst Elyse Greenspan maintains Everest Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EG#NYSE">EG</a>) with a Equal-Weight and lowers the price target from $406 to $402.

Wells Fargo Maintains Equal-Weight on Everest Group, Lowers Price Target to $402

Susquehanna analyst Biju Perincheril maintains AES (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AES#NYSE">AES</a>) with a Positive and lowers the price target from $24 to $21.

Susquehanna Maintains Positive on AES, Lowers Price Target to $21

Wells Fargo analyst Elyse Greenspan maintains Chubb (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CB#NYSE">CB</a>) with a Equal-Weight and raises the price target from $266 to $268.

Wells Fargo Maintains Equal-Weight on Chubb, Raises Price Target to $268

Wells Fargo analyst Eric Luebchow maintains Public Storage (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PSA#NYSE">PSA</a>) with a Overweight and lowers the price target from $375 to $365.

Wells Fargo Maintains Overweight on Public Storage, Lowers Price Target to $365

ZCAR

Zoomcar Holdings Shares Resume Trade Then Again Halted On Circuit Breaker, This Time To The Downside, Stock Now Up 87.1%

Wells Fargo analyst Chris Carey maintains Monster Beverage (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MNST#NASDAQ">MNST</a>) with a Overweight and raises the price target from $57 to $60.

MNST

Wells Fargo Maintains Overweight on Monster Beverage, Raises Price Target to $60

SoundCloud, the artist-first platform that empowers artists and fans to connect and share through music, and PubMatic, an independent technology company delivering digital advertising's supply chain of the future, announce a new strategic partnership offering SoundCloud's premium advertising inventory across PubMatic's suite of tools and solutions. Combining SoundCloud's extensive reach and engaged user base with PubMatic's advanced advertising solutions, the partnership creates a powerful platform for advertisers to connect with audiences on a global scale.
For the first time, PubMatic will offer SoundCloud global programmatic inventory on all video and display advertising on desktop and mobile app. This integration will give advertisers unprecedented access to SoundCloud's vibrant community of music lovers, offering a unique opportunity to engage with audiences in a meaningful and immersive way. With 400+ million tracks from 40+ million artists across 193 countries, SoundCloud is the largest audio discovery platform in the world. Its global audience of tastemakers, trendsetters, and creators are redefining audio culture. PubMatic will provide expertise, unique monetization opportunities, and access to differentiated demand. The collaboration with SoundCloud aligns with PubMatic's mission to fuel the endless potential of internet content creators.

PUBM

SoundCloud And PubMatic Announce A New Strategic Partnership Offering SoundCloud's Premium Advertising Inventory Across PubMatic's Suite Of Tools And Solutions Creating A Powerful Platform For Advertisers To Connect With Audiences On A Global Scale

Looking into the current session, Air Products &amp; Chemicals Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/APD#NYSE">APD</a>) shares are trading at $305.85, after a 0.08% drop. Over the past month, the stock decreased by 1.39%, but over the past year, it actually increased by 17.74%. With questionable short-term performance like this, and great long-term performance, long-term shareholders might want to start looking into the company's price-to-earnings ratio. 

<img src="https://www.benzinga.com/files/images/story/2024/1730819874_0.png" alt="Past Year Chart" />

<h3>A Look at Air Products &amp; Chemicals P/E Relative to Its Competitors</h3>
The P/E ratio measures the current share price to the company's EPS. It is used by long-term investors to analyze the company's current performance against it's past earnings, historical data and aggregate market data for the industry or the indices, such as S&amp;P 500. A higher P/E indicates that investors expect the company to perform better in the future, and the stock is probably overvalued, but not necessarily. It also could indicate that investors are willing to pay a higher share price currently, because they expect the company to perform better in the upcoming quarters. This leads investors to also remain optimistic about rising dividends in the future. 
Compared to the aggregate P/E ratio of the 51.67 in the Chemicals industry, Air Products &amp; Chemicals Inc. has a lower P/E ratio of 26.59. Shareholders might be inclined to think that the stock might perform worse than it's industry peers. It's also possible that the stock is undervalued. 

<img src="https://www.benzinga.com/files/images/story/2024/1730819874_1.png" alt="Guage" />

In summary, while the price-to-earnings ratio is a valuable tool for investors to evaluate a company's market performance, it should be used with caution. A low P/E ratio can be an indication of undervaluation, but it can also suggest weak growth prospects or financial instability. Moreover, the P/E ratio is just one of many metrics that investors should consider when making investment decisions, and it should be evaluated alongside other financial ratios, industry trends, and qualitative factors. By taking a comprehensive approach to analyzing a company's financial health, investors can make well-informed decisions that are more likely to lead to successful outcomes.

Intraday Update

A Look Into Air Products & Chemicals Inc's Price Over Earnings

Wells Fargo analyst Michael Brown maintains Brookfield Asset Mgmt (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BAM#NYSE">BAM</a>) with a Underweight and raises the price target from $48 to $51.

Wells Fargo Maintains Underweight on Brookfield Asset Mgmt, Raises Price Target to $51

Wells Fargo analyst Marc Torrente maintains Freshpet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FRPT#NASDAQ">FRPT</a>) with a Overweight and raises the price target from $157 to $175.

FRPT

Wells Fargo Maintains Overweight on Freshpet, Raises Price Target to $175

Wells Fargo analyst Michael Brown maintains TPG (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TPG#NASDAQ">TPG</a>) with a Overweight and raises the price target from $67 to $68.

Wells Fargo Maintains Overweight on TPG, Raises Price Target to $68

Wells Fargo analyst Elyse Greenspan maintains Baldwin Insurance (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BWIN#NASDAQ">BWIN</a>) with a Equal-Weight and lowers the price target from $46 to $43.

BWIN

Wells Fargo Maintains Equal-Weight on Baldwin Insurance, Lowers Price Target to $43

Zoomcar Holdings Shares Resume Trade Then Again Halt On Circuit Breaker To The Upside, Stock Now Up 98%

Wells Fargo analyst Daniel Politzer maintains Wynn Resorts (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WYNN#NASDAQ">WYNN</a>) with a Overweight and lowers the price target from $125 to $122.

WYNN

Wells Fargo Maintains Overweight on Wynn Resorts, Lowers Price Target to $122

Wells Fargo analyst Larry Biegelsen maintains Glaukos (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GKOS#NYSE">GKOS</a>) with a Overweight and raises the price target from $135 to $145.

GKOS

Wells Fargo Maintains Overweight on Glaukos, Raises Price Target to $145

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Synaptogenix (NASDAQ:<a href="https://investorplace.com/stock-quotes/snpx-stock-quote/">SNPX</a>) just reported results for the first quarter of 2024.<ul><li>Synaptogenix reported earnings per share of -41 cents.</li><li>The company did not report any revenue for the quarter.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT771245">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT771236">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2021/01/one-percenter-issues-urgent-warning/?cid=MKT499868&amp;eid=MKT793997">It doesn&rsquo;t matter if you have $500 or $5 million. Do this now.</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/earning-results/2024/05/snpx-stock-earnings-synaptogenix-for-q1-of-2024/">SNPX Stock Earnings: Synaptogenix Reported Results for Q1 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

SNPX Stock Earnings: Synaptogenix Reported Results for Q1 2024

An announcement from Synaptogenix (SNPX) is now available. Synaptogenix, Inc. has extended the term of Dr. Alan J. Tuchman, their CEO, through an a...

Synaptogenix CEO Dr. Tuchman's Tenure Extended Through 2024

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Synaptogenix (NASDAQ:<a href="https://investorplace.com/stock-quotes/snpx-stock-quote/">SNPX</a>) just reported results for the second quarter of 2024.<ul><li>Synaptogenix reported earnings per share of -$1.18.</li><li>The company did not report any revenue for the quarter.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/earning-results/2024/08/snpx-stock-earnings-synaptogenix-for-q2-of-2024/">SNPX Stock Earnings: Synaptogenix Reported Results for Q2 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

SNPX Stock Earnings: Synaptogenix Reported Results for Q2 2024

Synaptogenix announces $5M financing

Warning: SNPX is at high risk of performing badly

SNPX

Press Releases

Synaptogenix Joins Leading Neuroscientists and Academics as Speaker at USC-Sponsored Forum on Age-Related Diseases including Alzheimer's

Synaptogenix President Daniel L. Alkon, M.D. Honored for Scientific Presentation at USC-Sponsored Forum on Age-Related Diseases and Neurodegenerative Disorders

Small Cap

Stock Split

Synaptogenix Announces Reverse Stock Split to Maintain Nasdaq Listing

Synaptogenix Increases Stake in Innovative Psilocybin Drug Discovery Company through its Partnership with Cannasoul Analytics

Synaptogenix Regains Compliance with Nasdaq Minimum Bid Price Requirement for Continued Listing

Synaptogenix Applauds DEA Proposal to Reclassify Cannabis and Shares Expected Benefits to Cannasoul for Cannabinoid-Based Drug Discovery

Synaptogenix Announces FDA Authorization of IND Application for Clinical Trial for Bryostatin-1 in Multiple Sclerosis

Synaptogenix Announces New Collaboration with LSU Health New Orleans for Study of Proprietary Analogs in Spinal Cord Injury

Offerings

Synaptogenix Announces $5.0 Million Financing

Aditxt

Ainos

Aptevo Therapeutics

AquaBounty Technologies, Inc. - Common Stock

AquaBounty Techs

180 Life Sciences

Anitra

Bio-Path Hldgs

Chromocell Therapeutics Corporation Common Stock

Chromocell Therapeutics

Carmell

Genprex

GRI Bio

Pasithea Therapeutics Corp. - Common Stock

Pasithea Therapeutics

Lixte Biotechnology Holdings, Inc. - Common Stock

Lixte Biotechnology

Mainz Biomed

NuCana

Oncternal Therapeutics, Inc. - Common Stock

Oncternal Therapeutics

Psyence Biomedical Ltd. - Ordinary Shares

Psyence Biomedical

Polyrizon

Portage Biotech

Quoin Pharmaceuticals, Ltd. - American Depositary Shares

Quoin Pharmaceuticals

Shuttle Pharmaceuticals Holdings, Inc. - common stock

Shuttle Pharmaceuticals

SILO Pharma

Silexion Therapeutics Corp - Ordinary Shares

Comments

Synaptogenix

Synaptogenix (SNPX) Opzioni

No option chain data available. Please try again later

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO